Dowden Nathan J 4
4 · Entrada Therapeutics, Inc. · Filed Mar 11, 2026
Research Summary
AI-generated summary of this filing
Entrada Therapeutics (TRDA) President & COO Nathan J. Dowden Sells Shares
What Happened
Nathan J. Dowden, President & Chief Operating Officer of Entrada Therapeutics (TRDA), sold a total of 15,010 shares in two open-market transactions: 3,116 shares on 2026-03-09 at a weighted average price of $13.02 for proceeds of $40,583, and 11,894 shares on 2026-03-10 at a weighted average price of $13.05 for proceeds of $155,188. Total proceeds from both sales were about $195,771. These were sales (not purchases) and were executed under a pre-established trading plan.
Key Details
- Transaction dates and prices:
- 2026-03-09: 3,116 shares sold, weighted avg $13.02 (prices in range $13.00–$13.09). (Footnote F2)
- 2026-03-10: 11,894 shares sold, weighted avg $13.05 (prices in range $13.00–$13.20). (Footnote F3)
- Total shares sold: 15,010; total proceeds: ≈ $195,771.
- Shares owned after the transactions: Not disclosed in the information provided here (see the full Form 4 for post-transaction holdings).
- Footnotes: F1 — transactions were effected under a Rule 10b5-1 trading plan adopted March 7, 2025. F2/F3 — reported prices are weighted averages across multiple trades; the filer can provide a price-by-price breakdown on request.
- Filing: Form 4 filed 2026-03-11; appears timely relative to the trade dates.
Context
A Rule 10b5-1 plan is a pre-arranged trading program that allows insiders to sell shares on a set schedule and is commonly used to avoid the appearance of trading on non-public information. Sales under a 10b5-1 plan are typically considered routine; they do not by themselves indicate management’s view of the company’s prospects. Purchases tend to be more informative about insider confidence than scheduled sales.
Insider Transaction Report
- Sale
Common Stock
[F1][F2]2026-03-09$13.02/sh−3,116$40,583→ 210,482 total - Sale
Common Stock
[F1][F3]2026-03-10$13.05/sh−11,894$155,188→ 198,588 total
Footnotes (3)
- [F1]The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 7, 2025.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.00 to $13.09, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.00 to $13.20, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.